Title:Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
Volume: 24
Issue: 27
Author(s): Ron Batash , Noam Asna *, Pamela Schaffer, Nicole Francis and Moshe Schaffer
Affiliation:
- Barzilai Medical Center, Department of Oncology, Ashkelon,Israel
Keywords:
Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Abstract: Background: Glioblastoma multiforme (GBM) is the most common malignant
primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably
poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival
rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on
the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend
their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as
an adjuvant therapy cannot reduce the high rates of recurrence within a few months after
treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities
must be developed.
